Biotechnology company Celyad Oncology (Euronext Brussels:CYAD) announced on Thursday that it has sold its C-Cathez transendocardial catheter to CellProthera, including all intellectual property rights and technical documentation.
The catheter will serve as a core component in CellProthera's upcoming Phase 3 clinical trial, enabling targeted stem cell delivery to damaged cardiac tissue.
The agreement provides for up to EUR5m in milestone-based payments and future royalties on net sales. As the consideration is fully deferred, the transaction will not affect Celyad Oncology's current cash runway, which is expected to last through the third quarter of 2026.
CellProthera is a regenerative cell therapy developer specializing in ischemic diseases, with a leading program in myocardial infarction.
Eli Lilly reports positive Phase 1b results for VERVE-102
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
Artivion completes acquisition of Endospan following FDA approval of NEXUS Aortic Arch System
AstraZeneca wins US approval for Baxfendy as first aldosterone synthase inhibitor for hypertension
GSK's Arexvy gains expanded approval in Japan for at-risk adults aged 18-49
Tenaya Therapeutics reports interim RIDGE-1 data showing reduced arrhythmia burden with TN-401
AnaCardio reports Phase 1b/2a data showing cardiac function gains with AC01
Veradermics reports positive Phase 2/3 results for oral VDPHL01 in pattern hair loss treatment
Ondine Biomedical abstracts selected for 2026 World Congress on Infectious Diseases